SFM
ASND icon

Sphera Funds Management’s Ascendis Pharma A/S ASND Stock Holding History

Sphera Funds Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.83M Sell
8,000
-3,000
-27% -$673K 0.29% 80
2025
Q4 		$2.35M Buy
+11,000
New +$2.27M 0.45% 70
2022
Q2 		– Sell
-26,529
Closed -$3.11M – 60
2022
Q1 		$3.11M Buy
+26,529
New +$3.07M 0.44% 49
2021
Q1 		– Sell
-23,599
Closed -$3.94M – 174
2020
Q4 		$3.94M Sell
23,599
-9,000
-28% -$1.49M 0.35% 77
2020
Q3 		$5.03M Sell
32,599
-1,774
-5% -$255K 0.49% 61
2020
Q2 		$5.08M Buy
34,373
+1,800
+6% +$247K 0.48% 53
2020
Q1 		$3.67M Sell
32,573
-41,200
-56% -$5.35M 0.46% 43
2019
Q4 		$10.3M Hold
73,773
– – 0.85% 20
2019
Q3 		$7.11M Hold
73,773
– – 1.1% 24
2019
Q2 		$8.49M Buy
73,773
+5,500
+8% +$658K 1.16% 23
2019
Q1 		$8.04M Buy
68,273
+10,000
+17% +$876K 0.73% 26
2018
Q4 		$3.65M Sell
58,273
-34,400
-37% -$2.16M 0.41% 54
2018
Q3 		$6.57M Buy
92,673
+14,625
+19% +$1.01M 0.75% 31
2018
Q2 		$5.19M Sell
78,048
-17,426
-18% -$1.15M 0.72% 39
2018
Q1 		$6.24M Sell
95,474
-34,000
-26% -$1.91M 0.95% 32
2017
Q4 		$5.19M Hold
129,474
– – 0.61% 36
2017
Q3 		$4.69M Sell
129,474
-32,143
-20% -$922K 0.67% 42
2017
Q2 		$4.49M Sell
161,617
-93,838
-37% -$2.48M 0.76% 36
2017
Q1 		$7.15M Sell
255,455
-71,167
-22% -$1.8M 1.4% 14
2016
Q4 		$6.61M Buy
326,622
+63,122
+24% +$1.26M 1.67% 14
2016
Q3 		$5.3M Buy
263,500
+1,700
+0.6% +$28.1K 0.86% 26
2016
Q2 		$3.47M Buy
+261,800
New +$4.03M 0.9% 34
2015
Q2 		– Sell
-70,000
Closed -$1.22M – 133
2015
Q1 		$1.22M Buy
+70,000
New +$1.27M 0.13% 128

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sphera Funds Management's ASND Position: Q1 2026 in Review

Sphera Funds Management reduced its Ascendis Pharma A/S (ASND) stake by 27% in Q1 2026, selling an estimated $673K and leaving 8,000 shares worth $1.83M. The position accounts for 0.29% of the portfolio, ranked #80.

Sphera Funds Management first reported a position in ASND in Q1 2015 and has held it in 23 quarters since. The position peaked at $10.3M in Q4 2019. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • Sphera Funds Management held 8,000 shares of Ascendis Pharma A/S worth $1.83M as of Q1 2026.
  • Sphera Funds Management sold 3,000 Ascendis Pharma A/S shares in Q1 2026, an estimated $673K.
  • Ascendis Pharma A/S made up 0.29% of Sphera Funds Management's portfolio in Q1 2026, its #80 holding.
  • Sphera Funds Management first reported a position in Ascendis Pharma A/S in Q1 2015 and has held it in 23 quarters since.
  • Sphera Funds Management's Ascendis Pharma A/S position peaked at $10.3M in Q4 2019.
  • 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.